Israel Grijalva-Otero

Prof. Dr. Israel Grijalva-Otero

Instituto Mexicano del Seguro Social
+2
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2003 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
IGIsrael Grijalva-Otero
Israel Grijalva-Otero
GGGabriel Guízar‐Sahagún
Gabriel Guízar‐Sahagún
GCGilberto Castaneda‐Hernández
Gilberto Castaneda‐Hernández
DMDolores Mino
Dolores Mino
HMHéctor Maldonado‐Julián
Héctor Maldonado‐Julián
RARita Arenas‐Hernández
Rita Arenas‐Hernández

1 February 2019 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
CAC. Arreola-Mora
C. Arreola-Mora
JSJ. Silva-Pereyra
J. Silva-Pereyra
TFThalía Fernández
Thalía Fernández
MPM. Paredes-Cruz
M. Paredes-Cruz
BBB. Bertado-Cortés
B. Bertado-Cortés
IGIsrael Grijalva-Otero
Israel Grijalva-Otero

17 December 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
IGIsrael Grijalva-Otero
Israel Grijalva-Otero
CGConcepción Grajales-Muñiz
Concepción Grajales-Muñiz
CGCésar González-Bonilla
César González-Bonilla
VBVictor Hugo Borja-Aburto
Victor Hugo Borja-Aburto
MPMartín Paredes-Cruz
Martín Paredes-Cruz
ACArlette Areli Cervantes-Ocampo
Arlette Areli Cervantes-Ocampo
Background Zika, dengue and chikungunya viruses (ZIKV, CHIKV and DENV) are temporally associated with neurological diseases, such as Guillain-Barré syndrome (GBS). Because these three arboviruses coexist in Mexico, the frequency and severity of GBS could theoretically increase. This study aims to determine the association between these arboviruses and GBS in a Mexican population and to establish the clinical characteristics of the patients, including the severity of the infection. A case-control study was conducted (2016/07/01-2018/06/30) in Instituto Mexicano del Seguro Social (Mexican Social Security Institute) hospitals, using serum and urine samples that were collected to determine exposure to ZIKV, DENV, CHIKV by RT-qPCR and serology (IgM). For the categorical variables analysis, Pearson’s χ2 or Fisher exact tests were used, and the Mann-Whitney U test for continuous variables. To determine the association of GBS and viral infection diagnosis through laboratory and symptomatology before admission, we calculated the odds ratio (OR) and 95% confidence intervals (95%CI) using a 2x2 contingency table. A p-value ≤ 0.05 was considered as significant. Ninety-seven GBS cases and 184 controls were included. The association of GBS with ZIKV acute infection (OR, 8.04; 95% CI, 0.89–73.01, p = 0.047), as well as laboratory evidence of ZIKV infection (OR, 16.45; 95% CI, 2.03–133.56; p = 0.001) or Flavivirus (ZIKV and DENV) infection (OR, 6.35; 95% CI, 1.99–20.28; p = 0.001) was observed. Cases of GBS associated with ZIKV demonstrated a greater impairment of functional status and a higher percentage of mechanical ventilation. According to laboratory results, an association between ZIKV or ZIKV and DENV infection in patients with GBS was found. Cases of GBS associated with ZIKV exhibited a more severe clinical picture. Cases with co-infection were not found.

8 July 2008 in Spinal Cord
Verified
Journal Article
Closed access
GGGabriel Guízar-Sahagún
Gabriel Guízar-Sahagún
CRC A Rodríguez-Balderas
C A Rodríguez-Balderas
RFR E Franco-Bourland
R E Franco-Bourland
AMA Martínez-Cruz
A Martínez-Cruz
IGIsrael Grijalva-Otero
Israel Grijalva-Otero
IMI Madrazo
I Madrazo

26 March 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FGFernando Gongora-Rivera
Fernando Gongora-Rivera
IGIsrael Grijalva-Otero
Israel Grijalva-Otero
AIAdrian Infante-Valenzuela
Adrian Infante-Valenzuela
CCCarlos Cámara-Lemarroy
Carlos Cámara-Lemarroy
EGElvira Garza-González
Elvira Garza-González
GGGBS HU-IMSS Working Group
GBS HU-IMSS Working Group
Beginning August 2017, we conducted a prospective case-control investigation in Monterrey, Mexico to assess the association between Zika virus (ZIKV) and Guillain-Barré syndrome (GBS). For each of 50 GBS case-patients, we enrolled 2–3 afebrile controls (141 controls in total) matched by sex, age group, and presentation to same hospital within 7 days. PCR results for ZIKV in blood and/or urine were available on all subjects; serum ZIKV IgM antibody for 52% of case-patients and 80% of controls. Subjects were asked about antecedent illness in the two months prior to neurological onset (for case-patients) or interview (for controls). Laboratory evidence of ZIKV infection alone (PCR+ or IgM+) was not significantly different between case-patients and controls (OR: 1.26, 95% CI: 0.45–3.54) but antecedent symptomatic ZIKV infection [a typical ZIKV symptom (rash, joint pain, or conjunctivitis) plus laboratory evidence of ZIKV infection] was higher among case-patients (OR: 12.45, 95% CI: 1.45–106.64). GBS case-patients with laboratory evidence of ZIKV infection were significantly more likely to have had typical ZIKV symptoms than controls with laboratory evidence of ZIKV infection (OR: 17.5, 95% CI: 3.2–96.6). This association remained significant even when only GBS case-patients who were afebrile for 5 days before onset were included in the analysis, (OR 9.57 (95% CI: 1.07 to 85.35). During ZIKV epidemics, this study indicates that increases in GBS will occur primarily among those with antecedent symptomatic ZIKV.

28 December 2023 in Archives of Medical Research
Verified
Journal Article
Closed access
IGIsrael Grijalva-Otero
Israel Grijalva-Otero
EDErnesto Doncel-Pérez
Ernesto Doncel-Pérez